Investigational drug · Phase 2
GenSci048
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Uveitis, Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD).
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "GenSci048"
First trial start
2023
Dec 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GenSci048", any sponsor or status.
Conditions studied
As listed on its trial records.
- Uveitis
- Systemic Sclerosis Associated Interstitial Lung Disease
- Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)
- Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
- Endometriosis-related Pain
Approved drugs for the same conditions: Rheumatoid arthritis · Endometriosis · Immunology and inflammation · Endocrinology and women's health · Ophthalmology · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "GenSci048" as an intervention, largest first.
- Safety & Efffficacy of Genakumab in Patients With Frequent FlaresPivotal-lookingCompleted
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT05983445 · 313 participants · Start Jan 11, 2023 · Primary completion Apr 3, 2024
Drug: genakumab; placebo for Diprospan and 2 more · For: Acute Gout Arthritis
Sites: Shanghai, China
- A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated PainPivotal-lookingRecruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT06963177 · 200 participants (planned) · Start May 26, 2025 · Primary completion May 15, 2028
Drug: GenSci048; Placebo · For: Endometriosis-related Pain
Sites: Beijing, China
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07547995 · 74 participants (planned) · Start Jun 29, 2026 · Primary completion Dec 14, 2027
Drug: GenSci048; Placebo · For: Uveitis
Sites: Shanghai, China
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT06189495 · 30 participants (planned) · Start Dec 30, 2023 · Primary completion Mar 31, 2026
Drug: GenSci048; GenSci048 placebo · For: Systemic Sclerosis Associated Interstitial Lung Disease; Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD); Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Sites: Beijing, China; Wuhan, China; Jinan, China · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Population pharmacokinetics and exposure-response modelling of firsekibart (GenSci048) in patients with acute gout flare: Implications for fixed-dose optimization.
Wang K, Yang J, Xu F, et al. · Br J Clin Pharmacol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.